Antistaphylococcal activity of NVP-PDF713, a new peptide deformylase inhibitor compared with other agents
Abstract number: 902_p915
Resistance of staphylococci to b-lactams, quinolones and other agents is increasing and recently VISA as well as VRSA strains have been reported.
NVP-PDF713 is a new peptide deformylase inhibitor active against a wide variety of Gram-positive and -negative bacteria. The current study examines the activity of NVP-PDF713 compared with those of ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, vancomycin, teicoplanin, linezolid, ranbezolid, daptomycin, oritavancin and quinupristin/dalfopristin against 131 S. aureus (62 methicillin resistant) and 127 coagulase-negative staphylococci (60 methicillin resistant).
Microdilution using frozen trays containing cation-adjusted MuellerHinton broth and inocula of 1 × 105 CFU/mL with trays incubated in air.
MIC50 and MIC90 values (mg/mL) were as seen in the following table.
NVP-PDF713 was equally active against all staphylococcal strains (MICs <0.064 mg/mL), irrespective of susceptibility to other agents. Quinolone resistance was mainly seen in methicillin R strains. Vancomycin, linezolid, ranbezolid, daptomycin, oritavancin and quinupristin/dalfopristin were all active at MICs <4.0 mg/mL and teicoplanin was less active against coagulase-negative strains.
NVP-PDF713, a new peptide deformylase inhibitor, was active in vitro against staphylococci.
|Session name:||XXIst ISTH Congress|
|Back to top|